Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024. In the quarter to June 2026, revenue fell 39.1%, EPS grew 29.8% and free cash flow grew 24.8%, each against the same quarter a year earlier.
Follow VYGR
Voyager Therapeutics, Inc. (VYGR) EV/Sales
As of 16 October 2026, Voyager Therapeutics, Inc. (VYGR) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −9.1× (March 2016) to 89.7× (October 2017); the current reading is higher than 13% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | 12.43% |
| FY2024 | 0.8× | 20.54% |
| FY2023 | 0.6× | (77.41%) |
| FY2022 | 2.8× | — |
| FY2021 | −0.8× | — |
| FY2020 | 0.5× | (76.53%) |
| FY2019 | 2.1× | (89.01%) |
| FY2018 | 19.1× | (36.18%) |
| FY2017 | 29.9× | 231.53% |
| FY2016 | 9.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.8× | 14.80% |
| Mar 2026 | 2.4× | 185.16% |
| Dec 2025 | 0.8× | (59.60%) |
| Sep 2025 | 2.1× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −73.2× |
| VYGR Voyager Therapeutics, Inc. | 0.0× |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | 1.5× |
| CUE Cue Biopharma, Inc. compare | 2.4× |
| KRRO Korro Bio, Inc. compare | 8.4× |
| ABOS Acumen Pharmaceuticals, Inc. compare | 30.3× |
| HUMA Humacyte, Inc. compare | 40.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)